ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
“This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
- “This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
- “This study will evaluate RCT1100 as a potential novel treatment option for patients who do not have any approved therapies.
- The DNAI1 mRNA is intended to establish or restore proper ciliary function by addressing the underlying cause of the disease.
- This study brings us one step closer to improving the respiratory health and quality of life of people living with this disease.”